Role of Growth Hormone in the Treatment of Postmenopausal Osteoporosis
Postmenopausal osteoporosis is a common disorder that can lead to acute and chronic morbidity, affecting many in the population (1, 2). Surely, prophylactic and therapeutic strategies that prevent or improve this condition are welcome. In recent years much attention has been paid to secondary osteoporosis (known disorders and medications or such influences as diet, activity, and alcohol that negatively influence the skeleton), as well as to agents that inhibit osteolysis (gonadal steroids, calcitonin [CT], and the bisphosphonate compounds) (3). Increasingly, however, agents associated with more robust bone formation, such as low-dose, intermittent parathyroid hormone (PTH), sodium fluoride, growth hormone (GH), and various growth factors, are being considered as potential additions to our therapeutic armamentarium.
KeywordsPostmenopausal Osteoporosis Spine Bone Mineral Density Skeletal Effect Forearm Bone Mineral Density Intermittent Parathyroid Hormone
Unable to display preview. Download preview PDF.
- 2.Consensus conference: osteoporosis. JAMA 1984; 252:799–80.Google Scholar
- 5.Thorner MO, Vance ML, Horvath E, Kovacs K. The anterior pituitary. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology. 8th ed. Philadelphia: WB Saunders, 1992: 229–34.Google Scholar
- 26.Neer R, Slovik D, Daly M, Lo C, Potts JT, Nussbaum S. Treatment of postmenopausal osteoporosis with daily PTH plus calcitriol. In: Christiansen C, Overgaard K, eds. Osteoporosis. Copenhagen: Osteopress ApS, 1990: 1314–7.Google Scholar